PE20071061A1 - Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) - Google Patents

Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)

Info

Publication number
PE20071061A1
PE20071061A1 PE2006001710A PE2006001710A PE20071061A1 PE 20071061 A1 PE20071061 A1 PE 20071061A1 PE 2006001710 A PE2006001710 A PE 2006001710A PE 2006001710 A PE2006001710 A PE 2006001710A PE 20071061 A1 PE20071061 A1 PE 20071061A1
Authority
PE
Peru
Prior art keywords
peptidyl
pdf
carbonyl
benzoimidazol
pyrrolidin
Prior art date
Application number
PE2006001710A
Other languages
English (en)
Inventor
Arkadius Pichota
Jeyaraj Duraiswamy
Zheng Yin
Thomas Hugo Keller
Mark Schreiber
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37865850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20071061(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071061A1 publication Critical patent/PE20071061A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE CARBONILO DE FORMULA (I), DONDE n ES 1 O 2; X ES CH2, S O CHF; R1 ES -N(OH)CHO O -c(O)NH(OH); R2 ES ALQUILO, ALQUILARILO, ALQUILCICLOALQUILO, ENTRE OTROS; R3 ES TETRAZOLILO, 2-PIRIMIDINILO, 4--FENILIMIDAZOL-2-ILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{(R)-2-[(S)-2-(1H-BENZOIMIDAZOL-2-IL)-PIRROLIDIN-1-CARBONIL]HEXIL}-N-HIDROXIFORMAMIDA, N-{(R)-3-[(S)-2-(1H-BENZOIMIDAZOL-2-IL)-PIRROLIDIN-1-IL]-2-CICLOPENTILMETIL-3-OXOPROPIL}-N-HIDROXI-FORMAMIDA, N-{(R)-2-[(S)-2-(1H-BENZOIMIDAZOL-2-IL)-4-FLUORO-PIRROLIDIN-1-CARBONIL]-HEPTIL}-N-HIDROXI-FORMAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIDORES DE LA PEPTIDIL-DEFORMILASA (PDF) Y SON UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS TAL COMO LA TUBERCULOSIS, ENTRE OTRAS
PE2006001710A 2005-12-30 2006-12-28 Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) PE20071061A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG200508608-7A SG133452A1 (en) 2005-12-30 2005-12-30 Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases

Publications (1)

Publication Number Publication Date
PE20071061A1 true PE20071061A1 (es) 2007-12-06

Family

ID=37865850

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001710A PE20071061A1 (es) 2005-12-30 2006-12-28 Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)

Country Status (13)

Country Link
US (1) US20090318445A1 (es)
EP (1) EP1973898A1 (es)
JP (1) JP2009522232A (es)
KR (1) KR20080077655A (es)
CN (1) CN101346370A (es)
AR (1) AR058769A1 (es)
AU (1) AU2006334391A1 (es)
BR (1) BRPI0620655A2 (es)
CA (1) CA2629148A1 (es)
PE (1) PE20071061A1 (es)
RU (1) RU2008130925A (es)
SG (1) SG133452A1 (es)
WO (1) WO2007077186A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
KR20100123717A (ko) 2008-02-12 2010-11-24 브리스톨-마이어스 스큅 컴퍼니 Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
EP2332562A3 (en) * 2009-04-09 2011-09-28 Universität zu Köln Therapeutic agents for the treatment of tuberculosis, especially pulmonary tuberculosis
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242284B1 (en) * 2009-09-21 2012-08-14 The United States Of America As Represented By The United States Department Of Energy Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MX2012015292A (es) 2010-06-24 2013-05-30 Gilead Sciences Inc Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR102181318B1 (ko) 2012-04-17 2020-11-20 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료를 위한 화합물 및 방법
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
CN107074839A (zh) * 2013-08-29 2017-08-18 贝勒医学院 用于治疗代谢和体重相关的病症的组合物和方法
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017069275A1 (ja) * 2015-10-22 2017-04-27 田辺三菱製薬株式会社 新規二環性複素環化合物
US10738028B2 (en) 2016-05-11 2020-08-11 Rudong Ruien Pharmaceutical Technology Co. Ltd Spiro three-membered ring, spiro five-membered ring peptide deformylase inhibitor and use thereof in antibacteria and anti-tumor
WO2020120576A1 (en) * 2018-12-11 2020-06-18 Fundació Institut De Recerca Biomèdica (Irb Barcelona) p38α AUTOPHOSPHORYLATION INHIBITORS
CN109851614B (zh) * 2019-03-29 2023-01-13 中山大学 一类杂环类肽脱甲酰基酶抑制剂及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623190B2 (ja) * 1985-04-16 1994-03-30 サントリー株式会社 インヒビタ−活性を有するｎ−アシルピロリジン誘導体及びその製法並びに用途
AU2268401A (en) * 1999-12-17 2001-06-25 Versicor Inc Novel succinate compounds, compositions and methods of use and preparation
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ATE360014T1 (de) * 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen
GT200600196A (es) * 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina

Also Published As

Publication number Publication date
BRPI0620655A2 (pt) 2011-11-22
WO2007077186A8 (en) 2007-11-15
KR20080077655A (ko) 2008-08-25
RU2008130925A (ru) 2010-02-10
AU2006334391A1 (en) 2007-07-12
AR058769A1 (es) 2008-02-20
CA2629148A1 (en) 2007-07-12
EP1973898A1 (en) 2008-10-01
CN101346370A (zh) 2009-01-14
WO2007077186A1 (en) 2007-07-12
SG133452A1 (en) 2007-07-30
JP2009522232A (ja) 2009-06-11
US20090318445A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
PE20120993A1 (es) Derivados bifenilicos como antivirales
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
CR10095A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
PE20080552A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
ATE459622T1 (de) Tropanverbindungen
ATE435855T1 (de) Verbindungen mit agonistischer wirkung am beta2- adrenergen rezeptor und am muscarinischen rezeptor
DE602005023015D1 (de) Indolderivate als viruzide
NO20054185L (no) Methods of radiofluorination of biologically active vectors
TW200510405A (en) Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20091400A1 (es) Derivados de n-(2-amino-fenil)-amida como inhibidores de hdac
PE20120798A1 (es) Potentes inhibidores de molecula pequena de autofagia
PE20110344A1 (es) Derivados de etanodiamida como inhibidores de la integrasa del vih
BR0313385A (pt) Derivados de pirimidina-2,4-diona como inibidores de metaloproteinase da matriz
MX2007013624A (es) Inhibidores de proteina cinasa.
ATE503755T1 (de) Cgrp-rezeptorantagonisten
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren

Legal Events

Date Code Title Description
FC Refusal